CANY
HZNP

Caxton Associates (New York)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Caxton Associates (New York)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,742
Closed -$231K – 583
2019
Q1 		$231K Buy
+8,742
New +$207K 0.03% 312

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (New York)'s HZNP Position: Q2 2019 in Review

Caxton Associates (New York) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2019, closing a stake of 8,742 shares — an estimated $231K sold.

Caxton Associates (New York) first reported a position in HZNP in Q1 2019 and held it in 1 quarter. The position peaked at $231K in Q1 2019. 272 funds tracked by Wall St. Rank hold HZNP as of Q2 2019.

  • Caxton Associates (New York) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2019 after selling out during the quarter.
  • Caxton Associates (New York) sold 8,742 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2019, an estimated $231K.
  • Caxton Associates (New York) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 1 quarter.
  • Caxton Associates (New York)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $231K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2019.

Based on Caxton Associates (New York)'s 13F filing for Q2 2019, filed 14 Aug 2019.